Gizmodolatory and the future of PBRT

An article in the August 10 issue of The ASCO Post has recently asked the question, “Is proton-beam therapy facing a difficult future?… READ MORE …

“Basket” studies — another new class of clinical trial

Although it has no immediate relevance to the treatment of prostate cancer, it is worth noting that the results of the very first, completed and published “basket” type of clinical trial appear in this week’s issue of the New England Journal of Medicine (NEJM). … READ MORE …

Intraductal carcinoma of the prostate: of risk, outcomes, and Gleason scores

In a recent article in the American Journal of Surgical Pathology, Khani and Epstein have argued that patients initially diagnosed with intraductal carcinoma of the prostate (IDC-P) should have this reported as a separate class of prostate cancer, with no reference to the patients’ Gleason scores. … READ MORE …

HDRBT monotherapy in treatment of high-risk prostate cancer

Three randomized clinical trials (Sathya et al., 2005; Hoskin et al., 2012; and Guix et al., 2013) established the combination of external beam radiation therapy (EBRT) with a high dose rate brachytherapy (HDRBT) boost as a standard of care in the treatment of high-risk prostate cancer. … READ MORE …

How many “different” types of prostate cancer are there?

This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to sub-classify prostate cancers in the future in order to treat them most appropriately at the earliest relevant stage of development. … READ MORE …

Standardizing outcome measures in management of advanced prostate cancer

The Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement has finally been able to pull together a set of standardized patient-centered outcomes relevant to the evaluation of men in treatment for advanced forms of prostate cancer. … READ MORE …

Radiation therapy may improve survival even when PSA ≥ 75 ml/ml

Sometimes, when patients originally present with very high PSA levels, a negative bone scan, and a negative CT scan, they are put on permanent androgen deprivation  therapy (ADT) because the doctor just assumes it is micrometastatic. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,351 other followers